Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
NCT ID: NCT03686709
Last Updated: 2018-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
20 participants
INTERVENTIONAL
2018-06-19
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimizing Y90 Therapy for Radiation Lobectomy
NCT04390724
Accurate Dosimetry and Biomarkers Improve Survival in HCC Patients Treated With Resin 90 Yttrium (90Y)-Microspheres
NCT05227482
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
NCT04518748
Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System
NCT03889093
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
NCT06725121
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The first aim will examine radiation exposure to staff that are involved in handling Y90 microspheres. Radiation exposure to employees has only been somewhat addressed with a recent publication in the European Journal of Nuclear Medicine. Although this work contained key information for assessing exposure, the methods used were characteristic of european clinics and do not mirror the typical workflows seen in North American facilities. In this study, we will use new dosimeter technology to examine radiation exposure to the hands and body of the following clinical personnel using both TheraSphere and SIR-Spheres technology:
* Nuclear medicine technologists: responsible for drawing up, transporting, and disposal of Y90 microspheres doses.
* Interventional radiologists: responsible for administration of Y90 microspheres doses
The second aim will examine the use of a modular and portable detector device to provide real-time monitoring of radiation fields surrounding the microsphere administration systems. With current workflows, the final confirmation of whether the full dose was delivered is not assessed until after the procedure is completed and residual vial activities measured. This work will examine if this type of device might be useful in providing a real-time determination of whether the prescribed Y90 microspheres dose was fully delivered to the patient. Detectors will be placed at points throughout the delivery system and data recorded before, during, and after the injection of Y90. Time activity curves will be generated and assessed to determine activity levels near the dose vial and through distribution lines as the dose is injected. We will use various analysis techniques to identify and characterize the injection to determine if a dose administration was successful prior to removing the patient from the procedure room.
The third aim will use a modular detector device as well as post-radioembolization PET/CT to examine leaching of free Y90 following injection of Y90 microspheres. Some degree of leaching is expected with any labeled product, however, the degree of leaching involved with Y90 microspheres in vivo has yet to be studied in any detail. This pilot study will use two techniques to assess the impact and degree of leaching during Y90 dose administration.
The first step will use the modular detector device used in aim two of this proposal to measure radioactivity before, during, and after the Y90 dose administration. Detectors will be placed near the patient skin surface in close proximity to the lesion(s) being treated, as well as location distal to the catheter location in other body areas, including the extremities. Time activity curves will be generated from the data collected which will enable analysis of on-target and off-target activity. This data may also be used to assess flow kinetics which may improve isolation of the cause or route of leached Y90 should it be found.
The second step will involve imaging the patients using PET/CT. Typical Y90 radioembolization focuses on only imaging the liver for assessment of dosimetry following the dose administration. In this study, we will acquire a longer axial PET/CT covering an anatomical range from the top of the head to the lower extremities. This is equivalent to a typical PET/CT protocol used in melanoma imaging. The CT used will be a low-dose CT used only for anatomical localization and PET attenuation correction while the PET acquisition will only use the on-board Y90 for imaging and will not add any additional patient dose.
Using these two methods, we hope to monitor and assess leaching both during and after Y90 radioembolization to determine key concerns, such as the following:
* The frequency of detectable levels of leaching
* Physical extent of leaching throughout the body
* Patient radiation dose estimates associated with the leaching phenomenon
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SIR-Spheres Therapy Selection
Patient selected for SIR-spheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
Post therapy PET/CT Imaging
whole-body PET/CT following Y90 radioembolization
TheraSpheres Therapy Selection
Patient selected for TheraSpheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
Post therapy PET/CT Imaging
whole-body PET/CT following Y90 radioembolization
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Post therapy PET/CT Imaging
whole-body PET/CT following Y90 radioembolization
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to schedule and tolerate additional PET/CT imaging following therapy
* Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.
Exclusion Criteria
* Patients that cannot tolerate additional imaging procedures following therapy
* Patients that cannot tolerate the additional blood draws required for this study
* Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biocompatibles UK Ltd
INDUSTRY
University of Tennessee
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dustin Osborne, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Tennessee
Christopher Stephens, MD
Role: PRINCIPAL_INVESTIGATOR
University of Tennessee
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Tennessee Medical Center
Knoxville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4388
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.